Trastuzumab belongs to the class of medications called monoclonal antibodies.
This monoclonal antibody interferes with the receptor 2 of the human epidermal growth factor (HER2) which over-expresses in 20 -30% of the primary breast cancers and is associated with a worse prognosis.
This drug proves effective on some occasions.
Trastuzumab is also used with other medications to treat certain types of stomach cancer (HER2+) that have spread to other parts of the body (metastatic).
Gene or region studied